XERS Xeris Biopharma Holdings Forecast, Technical & Fundamental Analysis

XERS in upward trend: 10-day moving average moved above 50-day moving average on September 28, 2026

The 10-day moving average for XERS crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on XERS as a result. In 73 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for XERS just turned positive on September 21, 2026. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

XERS moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +9.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in 218 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for XERS moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 38 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 65 cases where XERS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

XERS broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XERS entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (107.527) is normal, around the industry mean (43.873). P/E Ratio (115.929) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.196) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.